Last checked at 9 Jun 2020 15:54
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR notification
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that, as part of its annual management incentivisation scheme, options ("Options") to subscribe for an aggregate of 324,474 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted on 5 June 2020 to each of Adam Hill, Chief Executive Officer, Matthew Hall, Chief Financial Officer, Matthew Luttrell, Chief Commercial Officer, and Tariq Sethi, Chief Scientific Officer as follows:
Name | Position | Number of Share Options Awarded | Exercise Price per Ordinary Share | Total Options held post grant | Total number of Ordinary Shares currently held | % of total issued share capital |
Adam Hill | Chief Executive Officer | 129,288 | £1.195 | 526,113 | 40,913 | 0.06% |
Matthew Hall | Chief Financial Officer | 134,936 | £1.195 | 295,486 | 11,935 | 0.02% |
Matthew Luttrell | Chief Commercial Officer | 42,677 | £1.195 | 266,361 | - | - |
Tariq Sethi | Chief Scientific Officer | 17,573 | £1.195 | 109,678 | - | - |
The Options have been granted under the 2016 Share Option Plan, have an exercise price of £1.195, being the closing price of Ordinary Shares on 4 June 2020, and vest annually in five equal parts from the date of grant until the fifth anniversary of grant.
This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| 1) Adam Hill 2) Matthew Hall 3) Matthew Luttrell 4) Tariq Sethi | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| 1) Chief Executive Officer 2) Chief Financial Officer 3) Chief Commercial Officer 4) Chief Scientific Officer | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Oncimmune Holdings plc | |||
b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)
| Nature of the transaction
| Grant of options | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
1) £1.195 | 129,288 | ||||
2) £1.195 | 134,936 | ||||
3) £1.195 | 42,677 | ||||
4) £1.195 | 17,573 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | As above | ||||
- Price | |||||
e)
| Date of the transaction
| 5 June 2020 | |||
f)
| Place of the transaction
| Outside a trading venue | |||
For further information:
Oncimmune Holdings plc
Ron Kirschner, General Counsel & Company Secretary
contact@oncimmune.co.uk